CD209 and rheumatoid arthritis: At the end of the differentiation (day 7), we can observe that JAK/STAT inhibition strongly decreased CD209 surface markers on Mo-DC from both RA, PsA patients and HC (Figure 4A, p < 0.001 and Supplementary Figure 4A).